Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT01392131 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma

NCT ID: NCT01217034 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib

TACTICS
Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular carcinoma (HCC) who are not candidates for surgical resection or percutaneous ablation therapy.

NCT ID: NCT01205828 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

ABT-888 and Temozolomide for Liver Cancer

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study is for people with liver cancer (also called hepatocellular carcinoma, or HCC in abbreviation). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide for patients with liver cancer. Temozolomide acts by damaging deoxyribonucleic acid (DNA) in rapidly dividing cells, in other words, cancer cells. ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the temozolomide and will hopefully increase the killing of cancer cells, and decrease the tumors in the body. ABT-888 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration (FDA) for use in liver cancer. This study will help find out what effects (good and bad) the combination of drugs, temozolomide and ABT-888, has on liver cancer. This research is being done because it is not known if ABT-888 will increase the effectiveness of temozolomide in liver cancer.

NCT ID: NCT01135056 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

SIRveNIB
Start date: July 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS). The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.

NCT ID: NCT00990860 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

START
Start date: February 2009
Phase: Phase 2
Study type: Interventional

TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology. This explains the strong scientific rationale for exploring the role of anti-angiogenic therapy such as sorafenib to remedy and strengthen the therapeutic efficacy of TACE to combat liver cancers. Sorafenib plays a prominent auxiliary role by further suppressing the tumor growth and prolonging the time to recurrence and progression. Performing TACE under sorafenib administration may have synergic effect on hepatic tumoral lesions.

NCT ID: NCT00986661 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Start date: October 2009
Phase: Phase 1
Study type: Interventional

This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.

NCT ID: NCT00805896 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma

Start date: December 2008
Phase: Phase 2
Study type: Interventional

Songyou Granule is a mixture of 6 herbs. Vitro and vivo studies showed that Songyou Granule can inhibit HCC cells grow, and HCC metastasis. Hypothesis of this study is that TACE plus Songyou Granule will improve outcome in patients with advanced hepatocellular carcinoma (HCC) compared with TACE.

NCT ID: NCT00797251 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression

Start date: September 2007
Phase: N/A
Study type: Observational

The use of intraoperative ultrasound (IOUS) allows us to perform new conservative hepatectomies. The investigators previously reported the systematic subsegmentectomy by IOUS-guided finger compression for segments 2-3, which is currently applied for patients with hepatocellular carcinoma (HCC)on cirrhosis. The investigators herein describe a novel technique, which consists in the systematic right posterior sectionectomy by IOUS-guided finger compression.

NCT ID: NCT00561522 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection

Start date: November 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.

NCT ID: NCT00423306 Active, not recruiting - Clinical trials for HEPATOCELLULAR CARCINOMA

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma